Mabwell Stock Hits Day Low of CNY 35 Amid Price Pressure

Mabwell (Shanghai) Bioscience Co., a large-cap player in the Pharmaceuticals & Biotechnology sector, experienced a notable decline today, with its stock price dropping by 3.98% as of February 24, 2026. The stock reached an intraday low of CNY 35.00, reflecting ongoing challenges in its financial performance. Over the past week, Mabwell's stock has decreased by 1.59%, while its performance over the last month shows a significant decline of 19.84%. In contrast, the China Shanghai Composite index has shown a modest decline of 1.26% for the day and a slight gain of 0.41% over the week. Despite a remarkable year-on-year performance increase of 120.88%, Mabwell's year-to-date performance stands at -8.42%, indicating volatility in its stock price. The company has faced challenges with management efficiency, as evidenced by a return on equity of -124.91% and a debt-to-equity ratio of 1.25. While Mabwell reported a substantial growth in net sales of 724.22% in its latest results, the overall financial health remains a concern due to ongoing losses and negative net worth.